Oprelvekin
Neumega (oprelvekin) is a protein pharmaceutical. Oprelvekin was first approved as Neumega on 1997-11-25. The pharmaceutical is active against interleukin-6 receptor subunit beta.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Oprelvekin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Neumega | oprelvekin | Wyeth | N-103694 DISCN | 1997-11-25 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2355 | Injection, oprelvekin, 5 mg |
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancytopenia | D010198 | HP_0001876 | D61.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 3 | 1 | — | — | 3 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | 1 | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Von willebrand diseases | D014842 | D68.0 | — | 4 | — | — | — | 4 | |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | 1 | — | — | — | 2 | |
| Leukemia | D007938 | C95 | — | 1 | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 1 | — | — | — | 1 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 1 | 1 | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | 1 | 1 | — | — | — | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | 1 | 1 | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemostatic disorders | D020141 | — | — | — | — | 1 | 1 | ||
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OPRELVEKIN |
| INN | oprelvekin |
| Description | Interleukin-11 precursor (IL-11) (Adipogenesis inhibitory factor) |
| Classification | Protein |
| Drug class | interleukins: interleukin-11 analogues and derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 145941-26-0 |
| RxCUI | 139994 |
| ChEMBL ID | CHEMBL1201573 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00038 |
| UNII ID | HM5641GA6F (ChemIDplus, GSRS) |
Target
Agency Approved
IL6ST
IL6ST
Organism
Homo sapiens
Gene name
IL6ST
Gene synonyms
NCBI Gene ID
Protein name
interleukin-6 receptor subunit beta
Protein synonyms
CD130, CD130 antigen, CDw130, gp130, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form, gp130, oncostatin M receptor, IL-6 receptor subunit beta, IL-6R subunit beta, interleukin receptor beta chain, Interleukin-6 signal transducer, Membrane glycoprotein 130, membrane glycoprotein gp130, Oncostatin-M receptor subunit alpha
Uniprot ID
Mouse ortholog
Il6st (16195)
interleukin-6 receptor subunit beta (Q00560)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 143 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
92 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more